1917P Updated survival and vaccine response from the NIPU trial: A randomised, phase II study evaluating nivolumab and ipilimumab with or without UV1 vaccination in patients with pleural mesothelioma

Autor: Haakensen, V.D., Öjlert, Å.K., Kefi, W., Thunold, S.M.H., Farooqi, S.J., Nowak, A.K., Chin, W.L., Grundberg, O., Szejniuk, W.M., Cedres Perez, S.M., Sørensen, J.B., Dalen, T.S., Lund-Iversen, M., Bjaanaes, M.M., Inderberg, E.M., Helland, A.

Publikováno v: In Annals of Oncology September 2024 35 Supplement 2:S1116-S1116

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Nivolumab and Ipilimumab +/- UV1 Vaccination as 2nd Line Treatment in Patients with Malignant Mesothelioma (the NIPU-Study)

Autor: Haakensen, V., Nowak, A., Ellingsen, E., Grundberg, O., Farooqi, S., Mcculloch, T., Cedres, S., Bjaanæs, M., Helland, Å.

Publikováno v: Haakensen, V, Nowak, A, Ellingsen, E, Grundberg, O, Farooqi, S, Mcculloch, T, Cedres, S, Bjaanæs, M & Helland, Å 2021, ' Nivolumab and Ipilimumab +/-UV1 Vaccination as 2nd Line Treatment in Patients with Malignant Mesothelioma (the NIPU-Study) ', Journal of Thoracic Oncology, vol. 16, no. 3, Suppl., P24.07, pp. S380 . https://doi.org/10.1016/j.jtho.2021.01.616

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::fe5979b8d791328e499e59bac80f9be0
https://vbn.aau.dk/da/publications/b7740f1c-054b-4053-82ca-04854db31bac

P24.07 Nivolumab and Ipilimumab +/- UV1 Vaccination as 2nd Line Treatment in Patients with Malignant Mesothelioma (the NIPU-Study)

Autor: Haakensen, V., Nowak, A., Ellingsen, E., Grundberg, O., Farooqi, S., Mcculloch, T., Cedres, S., Bjaanæs, M., Helland, Å.

Publikováno v: In Journal of Thoracic Oncology March 2021 16(3) Supplement:S380-S380

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.